Results of high-dose chemotherapy/hematopoietic stem cell transplantation (HDC/HSCT) in patients with disease refractory to primary chemotherapy.
| HDC . | n . | ~ 5 y† PFS % . | Reference . |
|---|---|---|---|
| †range 4 to 6 years to estimate Abbreviations: PFS, progression-free survival; TBI, total body irradiation; IFRT, involved field radiation therapy; BEAM, carmustine, etoposide, cytosine arabinoside, melphalan; CBV ± P, cyclophosphamide, carmustine, etoposide ± cisplatin; fTBI/ETOP/Cy, fractionated TBI, etoposide, cyclophosphamide; BCNU, carmustine; CCNU, lomustine. | |||
| Sequential program with melphalan + TBI or IFRT | 16 | 31 | 42 |
| BEAM | 46 | 33 | 22 |
| CBV±P | 30 | 42 | 43 |
| Etoposide + melphalan | 30 | 34 | 44 |
| BEAM (47 %) CBV (23 %) Other (20 %) TBI-based (5 %) | 290 | 30 | 73 |
| fTBI/ETOP/Cy BCNU/ETOP/Cy CCNU/ETOP/Cy | 29 | 50 | 74 |
| Variable | 75 | 32 | 3 |
| Variable | 25 | 40 | 75 |
| BEAM | 43 | 20 | 2 |
| Variable CBV (n = 47) | 62 | 15 | 45 |
| Variable | 122 | 38 | 4 |
| HDC . | n . | ~ 5 y† PFS % . | Reference . |
|---|---|---|---|
| †range 4 to 6 years to estimate Abbreviations: PFS, progression-free survival; TBI, total body irradiation; IFRT, involved field radiation therapy; BEAM, carmustine, etoposide, cytosine arabinoside, melphalan; CBV ± P, cyclophosphamide, carmustine, etoposide ± cisplatin; fTBI/ETOP/Cy, fractionated TBI, etoposide, cyclophosphamide; BCNU, carmustine; CCNU, lomustine. | |||
| Sequential program with melphalan + TBI or IFRT | 16 | 31 | 42 |
| BEAM | 46 | 33 | 22 |
| CBV±P | 30 | 42 | 43 |
| Etoposide + melphalan | 30 | 34 | 44 |
| BEAM (47 %) CBV (23 %) Other (20 %) TBI-based (5 %) | 290 | 30 | 73 |
| fTBI/ETOP/Cy BCNU/ETOP/Cy CCNU/ETOP/Cy | 29 | 50 | 74 |
| Variable | 75 | 32 | 3 |
| Variable | 25 | 40 | 75 |
| BEAM | 43 | 20 | 2 |
| Variable CBV (n = 47) | 62 | 15 | 45 |
| Variable | 122 | 38 | 4 |